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Abstract
Objective—To determine whether biomarkers of myocardial stress and fibrosis improve 
prediction of mode of death in patients with chronic heart failure.
Background—The two most common modes of death in patients with chronic heart failure are 
pump failure and sudden cardiac death. Prediction of mode of death may facilitate treatment 
decisions. The relationship between NT-proBNP, galectin-3, and ST2, biomarkers that reflect 
different pathogenic pathways in heart failure (myocardial stress and fibrosis), and mode of death 
is unknown.
Methods—HF-ACTION was a randomized controlled trial of exercise training vs. usual care in 
patients with chronic heart failure due to left ventricular systolic dysfunction (LVEF<35%). An 
independent clinical events committee prospectively adjudicated mode of death. NT-proBNP, 
galectin-3, and ST2 levels were assessed at baseline in 813 subjects. Associations between 
biomarkers and mode of death were assessed using cause-specific Cox-proportional hazards 
modeling, and interaction testing was used to measure differential association between biomarkers 
and pump failure versus sudden cardiac death. Discrimination and risk reclassification metrics 
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were used to assess the added value of galectin-3 and ST2 in predicting mode of death risk beyond 
a clinical model that included NT-proBNP.
Results—After a median follow up of 2.5 years, there were 155 deaths: 49 from pump failure 42 
from sudden cardiac death, and 64 from other causes. Elevations in all biomarkers were associated 
with increased risk of both pump failure and sudden cardiac death in both adjusted and unadjusted 
analyses. In each case, increases in the biomarker had a stronger association with pump failure 
than sudden cardiac death but this relationship was attenuated after adjustment for clinical risk 
factors. Clinical variables along with NT-proBNP levels were stronger predictors of pump failure 
(C statistic: 0.87) than sudden cardiac death (C statistic: 0.73). Addition of ST2 and galectin-3 led 
to improved net risk classification of 11% for sudden cardiac death, but not pump failure.
Conclusions—Clinical predictors along with NT-proBNP levels were strong predictors of pump 
failure risk, with insignificant incremental contributions of ST2 and galectin-3. Predictability of 
sudden cardiac death risk was less robust and enhanced by information provided by novel 
biomarkers.
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Introduction
Heart failure is among the leading causes of mortality and morbidity worldwide (1,2). The 
predominant modes of death in heart failure patients are pump failure and sudden cardiac 
death (3). Decisions regarding costly and complex interventions such as implantable 
cardioverter defibrillators (ICD) and left ventricular assist devices (LVAD) require careful 
weighing of the risks and benefits that may be significantly informed by understand the risk 
of specific modes of death (4). Current risk stratification models focus on predicting total 
mortality among patients with heart failure, but lack sensitivity and specificity when applied 
to prediction of cause-specific death (5). Plasma biomarkers that reflect the degree of 
myocardial stress and fibrosis, pathologic processes associated with the risk for pump failure 
and sudden cardiac death, may enhance risk stratification (6). On the basis of several large 
studies, three biomarkers have been cleared by the Food and Drug Administration (FDA) as 
aids for assessing prognosis of patients with chronic heart failure: natriuretic peptides (NT-
proBNP and BNP), galectin-3, and soluble ST2 (ST2)(7).
Several studies have reported on the overall prognostic implications of these biomarkers in 
patients with heart failure. However, whether their use alongside commonly available 
clinical measures can improve risk prediction of mode of death— on the basis of which 
complex clinical decisions such as ICD implantation in heart failure are regularly made—is 
unknown (8). For this reason, we sought to evaluate the relationships between elevated 
levels of NT-proBNP, galectin-3, ST2, and mode of death in a cohort of 813 chronic heart 
failure patients on optimal medical therapy.
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Details of the design, rationale, and primary results of the Heart failure and a controlled trial 
investigating outcomes of exercise training (HF-ACTION) study have been published 
elsewhere (9,10). Briefly, HF-ACTION (clinicaltrials.gov, NCT00047437) was a 
randomized clinical trial evaluating the effect of exercise training vs. usual care on long-
term morbidity and mortality in patients with chronic heart failure due to left ventricular 
systolic dysfunction (NYHA class II–IV, left ventricular ejection fraction (LVEF) < 35%). 
The primary endpoint of HF-ACTION was a composite of all-cause mortality and all-cause 
hospitalization over a median follow up of 2.5 years. HF-ACTION was approved by local 
Institutional Review Boards, and all enrolled patients provided written informed consent.
Adjudication of Mode of Death
An independent clinical events committee that comprised of 11 cardiologists blinded to 
treatment allocation reviewed and adjudicated all suspected events by consensus. Definitions 
were as follows:
Pump Failure—Death from worsening/intractable heart failure which generally occurred 
during hospitalization but could occur at home during hospice care. Terminal arrhythmias 
associated with pump failure deaths were classified as a pump failure death. Pump failure 
secondary to recent myocardial infarctions were not included.
Sudden Cardiac Death—Unexpected and otherwise unexplained death in a previously 
stable patient. This included patients who were comatose then died after attempted 
resuscitation. Patients in this category should have had recent human contact before the 
event. Patients who died who had been out of contact for prolonged or unknown periods of 
time were classified as unknown.
Other causes of death were myocardial infarction, cerebrovascular accident, cardiovascular 
procedure related, non-cardiovascular, and unknown. Follow-up events were prospectively 
ascertained every 6 months via direct patient contact and verified through death certificates, 
medical records, and contact with patients’ family members by dedicated research 
personnel.
Biomarker Measurements
A sub-set of patients enrolled in the HF-ACTION study who agreed to participate in the 
biomarker substudy underwent plasma collection of at baseline. Baseline blood samples 
were obtained on the same day as baseline exercise testing but were obtained prior to 
exercise. Samples were collected via peripheral vein into EDTA containing tubes, and then 
centrifuged immediately and stored at −70°C prior to analysis at core laboratories. Plasma 
NT-proBNP was measured by a standard electrochemiluminesence immunoassay (Elecsys 
proBNP, Roche Diagnostics, Indianapolis, IN). The inter-assay and intra-assay coefficients 
of variation were 2.9 and 6.1%, respectively. Galectin-3 was assessed using enzyme linked 
immunosorbent assays (BGM Galectin-3, BG Medicine, Waltham, MA). The inter-assay 
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and intra-assay variances were 5.6 and 8.6%, respectively. ST2 was measured from banked 
plasma samples via a highly sensitive sandwich monoclonal immunoassay (Presage ST2 
assay, Critical Diagnostics, New York, NY). The inter-assay and intra-assay coefficients of 
variation were less than 2.5% and 4.0%, respectively. The core laboratories were blinded to 
all clinical data.
Statistical Analysis
Baseline patient characteristics were described using medians and intra-quartile ranges or 
proportions, first in the entire cohort and then stratified by median level of each biomarker. 
For continuous variables, differences were compared using the ANOVA and Kruskal-Wallis 
tests. Categorical variables were compared using the chi-square and exact tests. The primary 
outcome variables of interests were death from pump failure and sudden cardiac death; other 
modes of death were treated as competing risks in the analysis. ST2 and NT-proBNP were 
log-base2 transformed to approximate normality. After assessment of various methods for 
handling galectin-3, including log transformation, the best model fit was provided by 
handling galectin-3 as a continuous variable with truncation at >20 ng/mL to avoid violation 
of the linearity assumption. To describe the timing and frequency of pump failure and 
sudden cardiac death and their relationship to the 3 biomarkers, cumulative incidence curves 
stratified by median level of each biomarker were plotted for each outcome. Using Gray’s 
K-sample test for comparing the cumulative incidence, P-values were derived that tested the 
null hypothesis of equality between the median-stratified sub-distributions (11).
To determine whether each biomarker was associated with pump failure or sudden cardiac 
death, and whether the association differed (in magnitude or direction) between the two 
outcomes, a series of cause-specific Cox proportional hazard models was fit. Cause-specific 
Kaplan-Meier curves were created in order to select the appropriate cause-specific modeling 
strategy; because if the curves crossed, an indicator for mode of death was included as a 
stratification variable in the cause-specific Cox regression model using the data 
augmentation method described by Lunn and McNeil (12). The association between each 
biomarker and outcome of interest was characterized by a hazard ratio (HR) and the 
corresponding 95% confidence interval (CI). To determine if each biomarker had a 
differential effect on mode of death, the interaction between biomarker and mode of death 
was tested in the cause-specific Cox regression model described above and the differential 
association P-value was reported. Models included adjustment first for a comprehensive set 
of predictors (BMI, sex, dosage of loop diuretic, LVEF, Canadian Cardiovascular Society 
angina classification, creatinine, and resting ECG ventricular conduction abnormalities) that 
had been identified as independently contributing to risk prediction in the final adjusted 
model in the overall HF-ACTION cohort for all-cause mortality, and then additionally for 
the other two biomarkers (13).
The prognostic utility of each biomarker was examined using two metrics. First, Therneau’s 
survival concordance index was provided to help assess each model’s discriminative ability. 
This metric is useful in determining a model’s ability to assign higher risk to individuals that 
experienced an event. Second, the categorical net reclassification improvement (NRI) was 
derived to help assess the added predictive ability of these novel biomarkers. The 
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“benchmark” model used to construct the NRI tables was the HF-ACTION adjustment 
model covariates and NT-proBNP. Patients were categorized as low/high risk based on the 
Kaplan-Meier failure rate at 4 years. ST2 and galectin-3 levels were added to the benchmark 
model individually and simultaneously in order to compare the reclassification of risk. Next, 
we estimated the expected number of cases and controls at 4-years and tabulated the NRI 
among cases and controls separately. All analyses were performed with SAS 9.3 (SAS 
Institute Incorporated, Cary, NC) and R 3.0.0 (R Development Core Team). A P-value ≤ 
0.05 was considered statistically significant for all analyses. The authors had full access to 
and take full responsibility for the integrity of the data.
Results
Baseline characteristics
Baseline plasma samples on NT-proBNP, galectin-3, and ST2 were available for 813 
patients, who were broadly similar to the HF-ACTION cohort as a whole (N=2331, data not 
shown). Baseline characteristics for the overall cohort and stratified by median biomarker 
levels are shown in Table 1. Median age of the study cohort was 59 years; 64% were white, 
and 71% were male. Median biomarker levels were 852 pg/mL (NT-proBNP), 13.9 ng/mL 
(galectin-3), and 23.8 pg/dL (ST2). Patients with elevated biomarker levels were older, had a 
higher prevalence of co-morbidities and NYHA function class, and impaired functional 
capacity on exercise testing.
Biomarkers and Risk of Mode of Death
During a median follow-up time of 32 months, there were 155 deaths. 49 were classified as 
due to pump failure, 42 as due to sudden cardiac death, 36 from other cardiac causes (CVA, 
cardiac procedure-related, fatal myocardial infarction, or unknown), and 28 from non-
cardiac causes. Figures 1 shows the cumulative probability of events according to mode of 
death. Figure 2 shows the cumulative incidences of non-cardiovascular, pump failure, and 
sudden cardiac deaths, stratified by median biomarker levels. As shown, the incidence of 
non-cardiovascular death was similar regardless of biomarker levels, whereas it differed 
significantly in case of cardiovascular causes of death. Patients with higher than median 
levels of NT-proBNP, galectin-3, and ST2 were more likely to die of pump failure 
(P<0.001, all). Sudden cardiac death occurred more commonly in patients with higher than 
median levels of NT-proBNP (P=0.05) and galectin-3 (P<0.01), while the association in the 
case of ST2 was of borderline significance (P=0.06).
To explore the differential association between each biomarker and mode of death, we first 
looked at the unadjusted effect, then adjusted for known clinical predictors of adverse 
outcomes, and lastly for the two remaining biomarkers (Table 2). After adjustment for 
clinical predictors, all three biomarkers remained significantly associated with both pump 
failure and sudden cardiac death. After additional adjustment for other biomarkers (ST
+galectin-3), NT-proBNP remained predictive of both pump failure and sudden cardiac 
death. In case of galectin-3, the associations with either mode of death were attenuated, but 
remained significant, after adjustment for clinical predictors and NT-proBNP, whereas ST2 
only retained a significant association with risk of pump failure.
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There was a differential association between pump failure and sudden cardiac death for all 
three biomarkers in the unadjusted models (Table 2). In all cases, increases in the biomarker 
had a stronger association with pump failure than with sudden cardiac death (P≤0.04). After 
adjustment for clinical risk factors, there was no further evidence of a significant differential 
association for NT-proBNP and galectin-3, whereas ST2 still had borderline evidence for a 
stronger association with pump failure (P=0.06).
Due to potential confounding that may results from patients with ICD therapies, we 
performed an additional sensitivity analysis by using ICD shocks as an SCD equivalent 
(Supplementary Table 1), and noted trends similar to those reported in Table 2. We also 
noted statistical evidence of a differentially stronger association of all three biomarkers with 
risk of pump failure.
Incremental Changes in Prediction of Mode of Death Using Biomarkers
To explore the clinical implications of our findings, we calculated changes in C statistics for 
prediction of pump failure and sudden cardiac death with incremental addition of 
biomarkers to the clinical model (Table 3). For pump failure, the C statistic for the clinical 
model was 0.82 (95% CI: 0.73–0.91), and similar to that for univariate biomarkers: 0.76 
(95% CI: 0.67–0.84) for galectin-3, 0.79 (95% CI: 0.70–0.88) for ST2, and 0.83 (95% CI: 
0.74–0.91) for NT-proBNP. Addition of NT-proBNP led to an increase in the C statistic 
(0.82→0.87); similarly subsequent additions of ST2 and galectin-3 increased the C statistic 
(0.87→0.89). The ability to discriminate among individuals that experienced a pump failure 
death was better than that for sudden cardiac death using the clinical model: 0.68 (95% CI: 
0.58–0.78)(Table 3). Addition of NT-proBNP to the clinical model improved the C statistic 
(0.68→0.73), and subsequent additions of ST2 and galectin-3 increased it to 0.75.
Due to potential insensitivities in detection of clinically important risk differences using 
AUC methods, we quantified the NRI for pump failure and sudden cardiac death. We 
calculated whether addition to the biomarkers to a risk model with clinic predictors and NT-
proBNP would lead to more appropriate classification of risk for each mode of death. 
Patients were classified into risk categories (low/high) of pump failure and sudden cardiac 
death based on a dichotomy of risk from a cause-specific model that included clinical 
covariates and NT-proBNP levels. The Kaplan-Meier failure rate at 4 years was chosen as 
the cut-off for high/low risk. For pump failure, this value was 10%, for sudden cardiac death 
this value was 8%. For the endpoint of pump failure (Figure 3; Supplementary Table 2), 
addition of ST2, galectin-3, or ST2 + galectin-3 to the clinical model + NT-proBNP did not 
result in a significant amount of net reclassification. In the case of sudden cardiac death 
(Figure 4; Supplementary Table 3), the addition of ST2 + galectin-3 led to a significant 
degree of appropriate reclassification [NRI: 0.11 (95% CI: 0.02 – 0.20]. These findings 
suggest that, after consideration of clinical risk factors and NT-proBNP, addition of novel 
biomarkers galectin-3 and ST2 may lead to improvements in risk classification of sudden 
cardiac death.
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In this analysis of 813 ambulatory systolic heart failure patients, we found that biomarkers 
of myocardial stress and fibrosis were strong independent predictors of death from pump 
failure and sudden cardiac death. When considering individual patient risk, prediction 
models comprising of clinical factors and NT-proBNP levels were stronger predictors of 
pump failure than sudden cardiac death. Inclusion of novel biomarkers improved risk 
discrimination for sudden cardiac death, but not pump failure. These findings suggest that 
readily available clinical measurements along with NT-proBNP are excellent predictors of 
risk of pump failure, and inclusion of novel biomarkers might play a role in improving 
prediction of sudden cardiac death.
We believe these data are of interest for several reasons. This is the first study to 
simultaneously report on the association between galectin-3, ST2, and mode specific death 
in patients with chronic heart failure (14,15). In a recent study of 876 ambulatory heart 
failure patients, Beyes-Genis and colleagues found that addition of ST2 to clinical risk 
factors and NT-proBNP improved prediction of all-cause and cardiovascular mortality, 
whereas the incremental predictive contribution of galectin-3 was trivial (16). Based on 
these results, they recommended incorporation of ST2, but not galectin-3, into clinical 
practice. Our study differed by focusing on the therapeutic implications of measuring 
additional biomarkers by studying the added value of novel biomarkers for prediction of 
cause-specific death, rather than all cause or cardiovascular mortality. This was because key 
clinical decisions in heart failure patients are generally based on forecasting risk of mode of 
death. Our findings also brought us to a different conclusion: knowledge of clinical variables 
and NT-proBNP levels already provide extremely accurate assessments of pump failure risk, 
whereas further inclusion of both ST2 and galectin-3 may improve prediction of sudden 
cardiac death. This underscores the need for validation of results in separate patient 
populations, as well as considering the therapeutic implications of reporting on purely 
prognostic performances of biomarkers, as these may be ambiguous when examined against 
a consolidated group of distinct clinical outcomes.
Second, we demonstrated a clear difference in our ability to predict pump failure versus 
sudden cardiac death using currently available data and novel heart failure biomarkers. 
Previously, only one study has examined this question: a case-control study of 36 patients 
reported on correlations between ST2 levels and risk of sudden cardiac death in heart failure, 
but was limited by its small size, reliance on observational data, and a lack of information 
about the competing risk of pump failure (17). Despite the theoretic possibility that 
galectin-3, a marker of myocardial fibrosis, might associate more strongly with sudden 
cardiac death, and ST2, a marker for biomechanical stretch, with pump failure, we did not 
find this to be the case (18,19). In fact, both biomarkers showed stronger associations with 
pump failure, and significant improvements in risk reclassification of sudden cardiac death 
occurred only with consideration of both biomarkers. Furthermore, clinical predictors and 
NT-proBNP yielded a C statistic of 0.87 for prediction of pump failure, while inclusion of 
all clinical factors and biomarkers led to a C statistic of 0.75 for prediction of sudden cardiac 
death. This suggests that pump failure may be a more clearly defined and predictable 
outcome that results from concomitant dysfunction in several overlapping biological 
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pathways, and the incremental prognostic value of novel biomarkers after inclusion of 
natriuretic peptides might be minimal. On the other hand, there is a need for improved 
prediction of sudden cardiac death risk and these results suggest that clinical use of ST2 and 
galectin-3 might be useful for this purpose.
Third, our study raises key questions about the added clinical utility of novel biomarkers in 
heart failure. While ST2 and galectin-3 have been FDA approved for use in heart failure 
based on their prognostic significance, their use at the bedside remains uncertain. 
Particularly promising has been the notion that adding these biomarkers to clinical data 
could assist clinicians with challenging decisions in instances where current prediction 
models lack sufficient accuracy, and interventions focus on use of expensive technologies 
(e.g. ICDs and LVADs), limited resources (e.g. cardiac transplantation), and end of life care. 
Since such interventions are aimed at preventing specific causes of cardiac death, examining 
the association of novel biomarkers with mode of death is of central significance prior to 
their widespread clinical use. Our finding that addition of ST2 and galectin-3 to clinically 
available data and NT-proBNP may enhance the ability to reclassify risk of sudden cardiac 
death implies that these biomarkers may play a future role in assisting physicians with 
recommendations surrounding use of ICDs. Moreover, our finding that currently available 
clinical predictors, along with consideration of NT-proBNP, are robust predictors of pump 
failure implies that use of novel biomarkers for this purpose may not improve clinical 
decision making to the degree that the added cost and complexity is justified. An additional 
point to consider is that clinical use of biomarkers can provide important objective, 
biologically meaningful, and reproducible measures of heart failure prognosis that may be of 
more value than currently used subjective, imprecise, and irreproducible measures. For 
example, qualification for use of ICD for prevention of sudden death in heart failure is based 
solely on NYHA class and LVEF, both highly variable and mediocre measures of disease 
state (20). Further studies are warranted to examine whether biomarker-based risk 
assessments might streamline and improve care of heart failure patients in a cost-effective 
manner. Lastly, undergoing studies are examining whether available treatments for heart 
failure, or novel inhibitors of ST2 or galectin-3 might modulate the disease process, and 
attenuate risk of specific outcomes, quantifiable with serum biomarker measurements (21–
23). Based on these studies, serial measures of these biomarkers may play a role in 
prediction of therapeutic response (24).
Several potential limitations of our study deserve consideration. First, our analysis was 
limited to the subset of HF-ACTION patients in whom plasma levels of NT-proBNP, 
galectin-3, and ST2 were available. However, this is the largest study of biomarkers and 
mode of death in heart failure to date, and the magnitudes of reported hazard ratios are 
consistent with previously reported risks of adverse clinical outcomes (14,15). Additionally, 
baseline characteristics of patients with and without available NT-proBNP levels were 
statistically similar. We did not have detailed information on appropriate versus 
inappropriate shocks in patients with ICDs; since appropriate shocks may represent a sudden 
cardiac death event, this may have led us to underestimate the occurrence of this mode of 
death; however, any misclassification of this kind would be expected to bias the results 
towards the null (25). We also provide a sensitivity analysis using ICD shocks as a SCD 
equivalent, with results largely consistent with our main findings. For purposes of 
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reclassification, we categorized patients as high/low risk, despite the absence of well-defined 
risk categories in heart failure. This likely led to a conservative estimation of the NRI, as 
increases in risk categories would be expected to increase degrees of reclassification. The 
study population for this analysis was derived from the HF-ACTION trial, and as such is 
susceptible to the limitations inherent in clinical trial populations such as limited follow-up 
time. Our study population consisted only of ambulatory patients with impaired ejection 
fraction (LVEF < 35%), so our results cannot be extrapolated to the population of patients 
with heart failure and preserved ejection fraction.
Conclusions
In summary, we found that novel biomarkers of myocardial stress and fibrosis were strongly 
associated with increased risk of death from pump failure and sudden cardiac death. 
Available clinical predictors along with NT-proBNP levels were strong predictors of pump 
failure risk, with insignificant incremental contributions with consideration of ST2 and 
galectin-3. Predictability of sudden cardiac death risk was less robust and enhanced by 
information provided by novel biomarkers. These findings suggest that despite the 
independent prognostic value of ST2 and galectin-3 elevations in heart failure, their clinical 
use might focus on improved prediction of sudden cardiac death risk.
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SCD sudden cardiac death
ICD implantable cardioverter defibrillators
LVAD Left ventricular assist device
NT-proBNP amino terminal proB-type natriuretic peptide
Soluble ST2 ST2
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HF-ACTION Heart failure and a controlled trial investigating outcomes of exercise 
training
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Figure 1. Kaplan-Meier Cause-Specific Survival Curves
The cumulative probability of events according to mode of death. Pump failure death was 
most common (N=49), followed by sudden cardiac death (N=42). 36 patients died from 
other cardiac causes (CVA, cardiac procedure-related, fatal myocardial infarction, or 
unknown), and 28 from non-cardiac causes.
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Figure 2. Cumulative Incidence of Sudden Cardiac Death, Pump Failure, and Non-
Cardiovascular Death According to Levels of Biomarkers
The cumulative incidence functions of adverse outcomes according to above versus below 
median biomarker level groups. Incidence of non-cardiovascular death was equivalent 
between patient groups. Patients with more than the medial level of all three biomarkers had 
a significantly greater incidence of pump failure (P<0.001, all). Incidence of sudden cardiac 
death was significantly greater in those with more than median levels of galectin-3 (P<0.01) 
and NT-proBNP (P=0.05), and of borderline significance in case of ST2 (P=0.06).
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Figure 3. Reclassification of 4 Year Predictive Probabilities of Pump Failure with Addition of 
Novel Biomarkers
Graphic representation of reclassification across low and high risk of pump failure and 
change in predicted probabilities with addition of galectin-3 and ST2 to Clinical model + 
NT-proBNP in entire cohort (top panel), cases (middle panel), and controls (bottom panel). 
Overlapping shading in risk categories represents the number of patients reclassified with 
addition of galectin-3 (left column), ST2 (middle column), and ST2+galectin-3 (right 
column). For example, among all patients (top panel), the addition of galectin-3 (left most 
column) moved 23 low risk patients into the high risk category, and 25 high risk patients to 
the low risk category.
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Figure 4. Reclassification of 4 Year Predictive Probabilities of Sudden Cardiac Death with 
Addition of Novel Biomarkers
Graphic representation of reclassification across low and high risk of sudden cardiac death 
and change in predicted probabilities with addition of galectin-3 and ST2 to Clinical model 
+ NT-proBNP in entire cohort (top panel), cases (middle panel), and controls (bottom 
panel). Overlapping shading in risk categories represents the number of patients reclassified 
with addition of galectin-3 (left column), ST2 (middle column), and ST2+galectin-3 (right 
column). For example, among all patients (top panel), the addition of galectin-3+ST2 (right 
most column) moved 38 low risk patients into the high risk category, and 51 high risk 
patients to the low risk category.
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